Cargando…
The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl
OBJECTIVE: To explore the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) with icosapent ethyl (IPE), we estimated (1) the number of ASCVD events and healthcare costs that could be prevented; a...
Autores principales: | Derington, Catherine G., Bress, Adam P., Herrick, Jennifer S., Fan, Wenjun, Wong, Nathan D., Andrade, Katherine E., Johnson, Jonathan, Philip, Sephy, Abrahamson, David, Jiao, Lixia, Bhatt, Deepak L., Weintraub, William S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097618/ https://www.ncbi.nlm.nih.gov/pubmed/35574517 http://dx.doi.org/10.1016/j.ajpc.2022.100345 |
Ejemplares similares
-
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022) -
Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
por: Toth, Peter P., et al.
Publicado: (2023) -
Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
por: Bhatt, Deepak L
Publicado: (2020) -
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT
por: Selvaraj, Senthil, et al.
Publicado: (2022) -
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022)